Gelonghui March 31st 丨Jingyou Pharmaceutical (00858.HK) announced that on March 31, 2023, Changchun Jingyou (an indirect non-wholly owned subsidiary of the company holding 73.11% of the company's interests) entered into a share repurchase agreement with the seller. According to this, the seller agreed to sell and Changchun Jingyou agreed to repurchase the shares to cancel the repurchase shares, which accounted for about 9.14% of Changchun Jingyou's total issued share capital, at a cost of RMB 4.4 million. After the share repurchase and share cancellation are completed, the Group's shares in Changchun Jingyou will increase to 80.46%, while Changchun Jingyou will continue to be an indirect non-wholly owned subsidiary of the Group.
精优药业(00858.HK)：集团于长春精优的股权将增至80.46%
Jingyou Pharmaceutical (00858.HK): The Group's shares in Changchun Jingyou will increase to 80.46%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.